
ãã«ã»ã²ã€ãã倧æè£œè¬äŒç€Ÿããã§ã€ã¹ããã¯ããã®æ¯æŽã§ãCDCã¯ãã€ããªãã£ã»ã³ãã¥ããã£ãã¯ã¯ãã³ãæšé²ããããã®ãã€ã³ãã«ãšã³ãµãŒããéãã®ãæ¯æŽããã€ãã·ã¢ãã£ãã«è³éãæäŸããã
å èšäºã¯ãã¡ããã/Click here to read the original article.
CDCã®Partnering for Vaccine Equity Programã¯ãå°æ°æ°æã人皮çãã€ããªãã£ã®ã³ãã¥ããã£ã«ãããã¯ã¯ãã³æåãå¢å ãããããã«ãã³ãã¥ããã£ããœãŒã·ã£ã«ã¡ãã£ã¢ã®ã€ã³ãã«ãšã³ãµãŒãèŠã€ããå ±é ¬ãæ¯æãã®ã«åœ¹ç«ã€ããŒã«ããããæäŸããŠããã
ç±³åœçŸç äºé²ç®¡çã»ã³ã¿ãŒïŒCDCïŒã¯ãCDC財å£ãšææºããæè²äººçš®ã®ã³ãã¥ããã£ã«ããã ãã¯ã¯ãã³ç¥è©±ããšéãããã®ã€ã³ãã«ãšã³ãµãŒãéãæ¹æ³ã«ã€ããŠãã³ãã¥ããã£ãåºç€ãšããçµç¹ãèšç·Žããããã®ããŒã«ãããã«è³éãæäŸããã
CDC財å£ã®ãããŒãªã¹ãã«ã¯ãäžçä¿å¥æ©é¢ããã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ããã¡ã€ã¶ãŒãã¡ã«ã¯ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ãªã©ã®ã¯ã¯ãã³ã¡ãŒã«ãŒãå«ãŸããŠããã
2022幎ã«åããŠå±éããããã®ããŒã«ãããã¯ãCDCã®Partnering for Vaccine Equity ProgramïŒP4VEïŒã«ãã£ãŠäœæãããäžé£ã®ãªãœãŒã¹ã®äžéšã§ããã
P4VEã®ã¯ã¯ãã³ã»ãªãœãŒã¹ã»ããã¯ãCDCãšç±³åœä¿å¥ç€ŸäŒçŠç¥çããã®8000äžãã«ãè¶ ãã婿éã«ãã£ãŠéå¶ãããŠãããããã«ã¯ãããŒã«ããããããŒãã©ã³ãã®ããžã¿ã«è³æã50以äžã®èšèªã§ã®ã¡ãã»ãŒãžã³ã°ãå«ãŸããã
å°åå£äœã¯ããã€ã³ãã«ãšã³ãµãŒã»ã¬ã€ãããå©çšããŠãã€ã³ãã«ãšã³ãµãŒèªèº«ã®å£°ã§å£äœã®ã¡ãã»ãŒãžãåºããŠãããã€ã³ãã«ãšã³ãµãŒã«æ¥è§Šããããšãã§ããã
ãã®ã¬ã€ãã§ã¯ãäžå ã®ã€ã³ãã«ãšã³ãµãŒãã€ãŸãéåºŠã«æåã§ãªããã§ããã°ãèªåã§æåãããã€ã³ãã«ãšã³ãµãŒãã¿ãŒã²ããã«ããããšãææ¡ããŠããã
ãã®ãããªã€ã³ãã«ãšã³ãµãŒã¯ã人皮çã»æ°æçãã€ããªãã£ã®ã³ãã¥ããã£ã§ã¯ã¯ãã³æ¥çš®ãä¿é²ããããã«ãå¹ åºããªãŒããæã€ã¡ãã»ã³ãžã£ãŒãšããŠå¹æçã«æŽ»åããããšãã§ããã
ãªã³ã©ã€ã³äžã§ã®åœ±é¿åãæå€§åããããã«ããã®ã¬ã€ãã§ã¯ããŸãã³ãã¥ããã£çµç¹ããé¢é£ããçµæŽãæã¡ãéå»ã«ãäžé©åãªãæçš¿ãããŠããªãé©åãªåè£è ãç¹å®ããããšãæšå¥šããŠããã
é©åãªã€ã³ãã«ãšã³ãµãŒãç¹å®ããããçµç¹ã¯ã€ã³ãã«ãšã³ãµãŒã«ãäŸãã°ã瀟äŒããçå€ãããã³ãã¥ããã£ã®äººã ã«å¯ŸããCOVID-19 ã¯ã¯ãã³ã®å®å šæ§ã«ã€ããŠã®ã¡ãã»ãŒãžãåºããããã®ããŒãããŒãäŸé Œããããšãã§ããã
ãã®ã¬ã€ãã§ã¯ãã€ã³ãã«ãšã³ãµãŒãšã®æé亀æžã®æ¹æ³ã«ã€ããŠã¢ããã€ã¹ããŠããã
ã€ã³ã¹ã¿ã°ã©ã ã§ã¯ã1,000ïœ10,000人ã®ãã©ãã¯ãŒãæã€ã€ã³ãã«ãšã³ãµãŒã¯éåžžãæçš¿1ä»¶ã«ã€ã10ïœ100ãã«ã®å ±é ¬ãåŸãŠããããã©ãã¯ãŒæ°ãå¢ããã«ã€ããŠå ±é ¬ã¯å¢å ããã100äžäººä»¥äžã®ãã©ãã¯ãŒãæã€ã€ã³ã¹ã¿ã°ã©ã ã®ã€ã³ãã«ãšã³ãµãŒã¯ãéåžž1æçš¿ããã1äžãã«ä»¥äžãåãåãã
TikTokã§ã¯ã1æçš¿ããã5ïœ25ãã«ããå§ãŸãã100äžäººä»¥äžã®ãã©ãã¯ãŒãããå Žåã¯1æçš¿ããã2,500ãã«ä»¥äžã«ãªãããšãããã
ãã®ã¬ã€ãã§ã¯ãçµç¹ã¯ã€ã³ãã«ãšã³ãµãŒã®çºèšå 容ãã³ã³ãããŒã«ããããšïŒæçš¿ãå°æ¬éãã«èãããªãããã«ããããšïŒãšãã€ã³ãã«ãšã³ãµãŒã®åæ§ãçºæ®ãããããšã®ãã©ã³ã¹ãåãããšãæšå¥šããŠããã
å¥çŽãçµãã åŸãçµç¹ã¯ã€ã³ãã«ãšã³ãµãŒã«ã³ã³ãã³ããæäŸããæçš¿ãããããšãã§ããã
ããã®ã¬ã€ãã«ãããšããã€ã³ãã«ãšã³ãµãŒã«ã¯ãæŒãã€ãã宣äŒã«èãããå¯èœæ§ã®ããæ£ç¢ºãªå°æ¬ã«ãã ããã®ã§ã¯ãªããçµç¹ããæäŸãããããŒãã³ã°ãã€ã³ãã䜿ãããäŸé Œããã®ããã¹ããã ãšããã
P4VEã¯èª°ã®å©çãä¿é²ããŠããã®ãïŒ
ãªãœãŒã¹ã»ããã®ãã€ã³ãã«ãšã³ãµãŒã»ã¬ã€ããããŒã«ãããã¯ãP4VEãäž»å¬ããæ§ã ãªããã°ã©ã ã®äžäŸã«éãããP4VEã¯COVID-19ã人皮çã»æ°æçãã€ããªãã£ã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³æ¥çš®ã«ããããã¯ã¯ãã³ã®å ¬å¹³æ§ã®ä¿é²ããç®çãšããæ°åãã«ã®æè³ãåããŠããã
2021幎ã«COVID-19ã®è¿œå è³éã§éå§ãããP4VEã¯ãäž»ã«CDCã®ã¯ã¯ãã³æšé²ã¡ãã»ãŒãžãåºããããã«å°åå£äœã«è³éãæäŸããããšãç®çãšããŠããã2021幎ã ãã§å šç±³ã®äººçš®çã»æ°æçãã€ããªãã£ã察象ãšãã500以äžã®å£äœã«1å5600äžãã«ä»¥äžãåé ããã¯ã¯ãã³æšé²ãå³ã£ãŠããã
P4VEã®æŽ»åã¯ãCDC財å£ãã¢ãŒãã³ã»ã€ã³ã¹ãã£ãã¥ãŒããå«ãè€æ°ã®éå¶å©å£äœã«ãã£ãŠéå¶ãããŠãããP4VEã®è³éã¯äž»ã«ã³ãã¥ããã£ããŒã¹ã®å£äœã«åé ãããã
ã€ã³ãã«ãšã³ãµãŒã»ã¬ã€ããã®ãããªãªãœãŒã¹ãäœæããP4VEãªãœãŒã¹ã»ããã®éå¶ã«å ããP4VEã«ãããCDC財å£ã®åœ¹å²ã«ã¯ã31ã®ã³ãã¥ããã£çµç¹ãšææºããã³ãã¥ããã£ã§ã®ã¯ã¯ãã³æåãå¢ããããšãå«ãŸããã
ãŸãã5ã€ã®ç¡åã®ããžã¿ã«ã»ããŒã±ãã£ã³ã°ããã³ã¡ãã£ã¢ã»ããŒãããŒãšååããããœãŒã·ã£ã«ã¡ãã£ã¢ã»ãã£ã³ãã«ã§ã¯ã¯ãã³ã«é¢ãã誀ã£ãæ å ±ãšéããäºé²æ¥çš®ã«æ Œå·®ãããå°å瀟äŒã§ããžã¿ã«ã»ãã«ã¹ã»ãªãã©ã·ãŒãä¿é²ãããã
CDC財å£ã¯ãæ°éè³éãCDCãšCDCã®ããã°ã©ã ã«æå ¥ããããã«è°äŒã«ãã£ãŠèšç«ãããç¬ç«éå¶å©å£äœã§ããã1995幎ã®èšç«ãã2023幎ãŸã§ãCDC財å£ã¯åœå å€ã®ããã°ã©ã ã®ããã«æ°éããã³æ¿åºãããŒãã22åãã«ãéããã
ããã°ã©ã ã¯ãå ¬è¡è¡çæ©é¢ãžã®ä¿¡é Œãé«ããããã®ããã«ã¹ã»ã³ãã¥ãã±ãŒã·ã§ã³ããããç±³åœå ã®å¥åº·ç£èŠãæ¹åããããã®ãããŒã¿è¿ä»£åããããã«ãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãšååããŠã¢ããªã«ã«çŸç ç£èŠã©ãã建èšããããã¯ã¯ãã³ã»ããããäœæããããããã°ããŒãã«ã»ãã«ã¹ãã»ãã¥ãªãã£ã»ã€ãã·ã¢ãã£ããŸã§å€å²ã«ãããã
CDC財å£ã¯ãå ¬è¡è¡ç財å£ããããŒãã»ãŠããã»ãžã§ã³ãœã³è²¡å£ãããã¯ãã§ã©ãŒè²¡å£ããã¥ãŒã»ãã£ãªã¿ãã«ã»ãã©ã¹ããGaviãªã©ãå ¬è¡è¡çåéã®ä»ã®äž»èŠãªè²¡å£ããç±³åœã®ã»ãšãã©ã®å·ãããè³éæäŸãåããŠããã
ãŸããã¡ã«ã¯ããã¡ã€ã¶ãŒã®ãããªäŒæ¥ããçŽæ¥ããããã¯ã¢ããæ å財å£ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³è²¡å£ãã°ã©ã¯ãœã»ã¹ãã¹ã¯ã©ã€ã³è²¡å£ãã¡ã«ã¯ã»ãã©ãŒã»ãã¶ãŒãºãªã©ã®æ åéšéãããè³éãåŸãŠããã
ãã§ã€ã¹ããã¯ã®èŠªäŒç€Ÿã§ããã¡ã¿ç€Ÿãšã°ãŒã°ã«ããCDC財å£ãžã®å¯ä»è ãšããŠåãé£ããŠããã
CDCã¯2021幎以æ¥ããæåçã«èª¿æŽããããã¯ã¯ãã³æšé²è³æã®äœæããCOVID-19ã ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãå šç±³ã®æè²äººçš®ã®ã³ãã¥ããã£ã«åºããããã®ã圱é¿åã®ããã¡ãã»ã³ãžã£ãŒãã®è²æã®ããã«ãäœåãã«ãã®å©æ éãæ¯æã£ãŠããã
2021幎3æããã€ãã³æ¿æš©ã¯ãŸãããã¯ã¯ãã³ãžã®ä¿¡é Œã匷åãã ãããã®å°åã®ã€ãã·ã¢ãããæ¯æŽããããã«ãCDCã«30åãã«ãèšäžããã
ãã®ãããªå©æéã¯ããéé¢ãšéé¢ã«é¢é£ããé£éŠåœä»€ãã®å·è¡ã«ãããŠæ¿åºãæ¯æŽããããšãæ¡ä»¶ãšããŠããã
婿éåé è ã¯ãŸããå°åã¬ãã«ã®ããŒã¿ãåéããCDCã«æäŸããããšã矩åä»ããããŠããã
P4VEã®ãããªãããžã§ã¯ãã¯ãCOVID-19ã®ä»å ¥ã«å¯Ÿããè³éãæ¯æžããäžãCOVID-19åŸã®ãã³ãããã¯æã«ãããããã°ã©ã ã®ç¶ç¶ãæ£åœåããããã«ã察象éå£ãåã©ãããã®ä»ã®ãåªå çéå£ãã«æ¡å€§ããäžæ¹ã§ãã¯ã¯ãã³ãæšé²ããéæ¿åºã®ãä¿¡é Œã§ããã¡ãã»ã³ãžã£ãŒããè²æãããšããåãäœæ¥ãç¶ç¶ãããããæŠç¥ãæç¢ºã«è»¢æããŠããã